Tomáš Cihlář (vice president, and senior director, Biology)
Products
AmBisome
Atripla
Biktarvy
Complera
Cayston
Descovy
Emtriva
Epclusa
Genvoya
Harvoni
Hepsera
Letairis
Lexiscan
Macugen
Odefsey
Ranexa
Sovaldi
Stribild
Tamiflu
Truvada
Tybost
Veklury
Vemlidy
Viread
Vosevi
Yescarta
Zydelig
Revenue
US$27.12 billion (2023)
Operating income
US$7.605 billion (2023)
Net income
US$5.613 billion (2023)
Total assets
US$62.13 billion (2023)
Total equity
US$22.83 billion (2023)
Number of employees
c. 18,000 (2023)
Website
gilead.com
Footnotes / references [1]
Gilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its IPO in 1992, and successfully developed drugs like Tamiflu and Vistide that decade.
In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs.
The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.[2][3][4][5][6]
^"Gilead Sciences, Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. February 23, 2024.
^Cite error: The named reference WSJ2019 was invoked but never defined (see the help page).
^Cite error: The named reference Stanton2 was invoked but never defined (see the help page).
^Cite error: The named reference Silverman was invoked but never defined (see the help page).
^Cite error: The named reference Bloomberg2015 was invoked but never defined (see the help page).
^Cite error: The named reference WaPo2019a was invoked but never defined (see the help page).
GileadSciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing...
broad-spectrum antiviral medication developed by the biopharmaceutical company GileadSciences. It is administered via injection into a vein. During the COVID‑19...
2017, GileadSciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, a 29% premium on the share price. Gilead made...
it to be a first-in-class medication. Lenacapavir was developed by GileadSciences. As of 2021, it is in phase II/III clinical trials. It is being investigated...
signed license agreements with Bristol-Myers Squibb for Atazanavir and GileadSciences for Tenofovir as part of their Global Access Programs. In 2012, Roche...
Prague, by Antonín Holý, and developed by GileadSciences and is marketed with the brand name Vistide by Gilead in the US, and by Pfizer elsewhere. Cidofovir...
Indian pharma companies that received the licensing agreements from the GileadSciences to produce remdesivir. Zydus Cadila's major shareholder remains the...
transcriptase inhibitor and is a prodrug of tenofovir. It was developed by GileadSciences based on the protide technology of Chris McGuigan and is applied in...
Extended-Release Tablets, for Oral Use. Full Prescribing Information". GileadSciences, Inc. Foster City, CA 94404. Retrieved 8 September 2016. Rosa GM, Dorighi...
company GileadSciences led to the investigation of PMPA's potential as a treatment for HIV infected patients. In 1997 researchers from Gilead and the...
for the treatment of cancer. In 2020, the company was acquired by GileadSciences. Immunomedics was founded in July 1982 by David M. Goldenberg. Michael...
was first tested in people in 2010. In 2011, GileadSciences bought Pharmasset for about $11 billion. Gilead submitted the New Drug Application for sofosbuvir...
compound dolutegravir by scientists at GileadSciences. In vitro and clinical results were presented by Gilead in the summer of 2016. In 2016, bictegravir...
by Emory in 1996. Triangle Pharmaceuticals was acquired in 2003 by GileadSciences, which completed development and now markets the product with the brand...
hepatitis C that was developed by GileadSciences. After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a...
The applicant for this medicinal product is GileadSciences Ireland UC. 19 August 2020: FDA rejects Gilead’s filing for approval of filgotinib over toxicity...
(GS-5245, ATV006) is an isobutyric ester prodrug of GS-441524 made by GileadSciences that is currently in Phase III trials for the outpatient treatment...
Sacituzumab govitecan, sold under the brand name Trodelvy by GileadSciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate...
and Biochemistry, Academy of Sciences of the Czech Republic by Antonín Holý, and the drug was developed by GileadSciences for HIV with the brand name...
Global Information
US$27.12 billion (2023)
US$7.605 billion (2023)